We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client‐owned dogs with allergic dermatitis.
- Authors
Van Brussel, Leen; Moyaert, Hilde; Escalada, Monica; Mahabir, Sean P.; Stegemann, Michael R.
- Abstract
In this study, a 53% reduction in pruritus was observed 6 days after the start of lokivetmab treatment which is in line with what was previously reported for oclacitinib (55%).13 Equally, a peak in pruritus reduction was observed 14 days after injection of lokivetmab treatment The antipruritic activity of lokivetmab remained unchanged after D14, and on D28 there was still a 58% reduction in pruritus in the treated animals. B Hypothesis/Objectives - b To demonstrate the efficacy and safety of lokivetmab (canine anti-IL-31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs. Owner-assessed pVAS On D0, the pre-treatment mean pruritus score was 69 in the control group versus 70 in the lokivetmab-treated group. The treatment dispenser drew up the correct dose of injectable treatment (lokivetmab or saline, with identical appearance) into a syringe and provided it to the investigator for administration.
- Subjects
CONTACT dermatitis; ITCHING; GERMAN shepherd dog; DOGS; CLINICAL trials; DOG breeds; MEDICAL masks
- Publication
Veterinary Dermatology, 2021, Vol 32, Issue 5, p477
- ISSN
0959-4493
- Publication type
Article
- DOI
10.1111/vde.12984